Patient Guide: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 29 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04561362
Status: 🟢 Enrolling Now
Condition: Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 29 locations across the country.

Top locations include:
  • • Denver, Colorado
  • • Ocala, Florida
  • • Orlando, Florida
  • • And 26 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies - Join Clinical Trial NCTNCT04561362

How to Join This Clinical Trial - NCTNCT04561362

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT04561362 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 29 locations. Find a study site near you:

Clinical Research Site

Denver, Colorado 80218 - United States

Status: RECRUITING

Clinical Research Site

Ocala, Florida 34474 - United States

Status: RECRUITING

Clinical Research Site

Orlando, Florida 34747 - United States

Status: RECRUITING

Clinical Research Site

Lafayette, Indiana 47905 - United States

Status: WITHDRAWN

Clinical Research Site

Louisville, Kentucky 40207 - United States

Status: WITHDRAWN

Clinical Research Site

Las Vegas, Nevada 89169 - United States

Status: WITHDRAWN

Clinical Research Site

New York, New York 10029 - United States

Status: RECRUITING

Clinical Research Site

Cleveland, Ohio 44106 - United States

Status: RECRUITING

Clinical Research Site

Philadelphia, Pennsylvania 19107 - United States

Status: RECRUITING

Clinical Research Site

Nashville, Tennessee 37203 - United States

Status: RECRUITING

And 19 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships